Redefining the diagnostic pathway for pulmonary nocardiosis: The imperative for early metagenomic sequencing

Abstract

In this article, we comment on the pivotal article by Wang et al. We focus on the critical intersection of advanced imaging and molecular diagnostics highlighted by their findings. The study delineates specific high-risk computed tomography patterns, notably consolidation with nodules/cavities, particularly in immunocompromised hosts or patients with bronchiectasis, that should serve as immediate red flags for pulmonary nocardiosis. Traditionally, diagnosis has relied on slow-growing cultures, leading to dangerous therapeutic delays. This editorial argues that the presence of these defined radiologic signatures may represent an important step toward refining the diagnostic pathway for pulmonary nocardiosis. Rather than a confirmatory last resort, metagenomic next-generation sequencing should be deployed as a first-line investigative tool following high-suspicion imaging. We propose a concrete, integrated diagnostic algorithm where imaging triage triggers parallel processing with metagenomic next-generation sequencing and conventional microbiology. This synergy of morphology and metagenomics promises to expedite species-specific diagnosis, guide timely targeted therapy, and ultimately improve outcomes for patients with this challenging and often elusive infection.

Key Words: Pulmonary nocardiosis; Metagenomic next-generation sequencing; Diagnostic algorithm; Computed tomography; Bronchiectasis; Immunosuppression

Core Tip: The large-scale study by Wang et al defines key computed tomography patterns that predict pulmonary nocardiosis. This article argues these imaging findings should trigger an immediate diagnostic shift, positioning metagenomic next-generation sequencing as a primary, not secondary, tool. A new algorithm integrating radiologic triage with rapid metagenomic next-generation sequencing testing can dramatically reduce diagnostic delay, enabling faster targeted treatment.

INTRODUCTION

Pulmonary nocardiosis, an insidious infection caused by aerobic actinomycetes of the genus Nocardia, continues to confound clinicians and radiologists alike[1]. Its nonspecific clinical presentation often masquerades as tuberculosis, invasive fungal disease, or malignancy, and the fastidious growth of the organism in culture creates a perfect storm for diagnostic delay, often spanning critical weeks[1,2]. During this interval, especially in immunocompromised hosts, the infection can progress relentlessly. The seminal work by Wang et al[3] analyzing 102 cases, provides a transformative roadmap out of this diagnostic dilemma. By rigorously correlating computed tomography (CT) patterns with clinical and microbiological data, the authors move beyond descriptive radiology to provide actionable intelligence. Their findings compellingly demonstrate that specific imaging phenotypes, i.e., consolidation with nodules/cavities, complex patterns in immunosuppressed patients, and association with bronchiectasis, are potent sentinels for the disease. This article contends that such precise radiologic definition now supports reconsideration of current diagnostic workflows and highlights an opportunity for more integrated strategies with the rapid power of metagenomic next-generation sequencing (mNGS) from the moment of suspicion.

THE RADIOLOGIC SENTINEL: FROM PATTERN RECOGNITION TO ACTIONABLE TRIAGE

From an imaging standpoint, CT has remained indispensable for detecting pulmonary nocardiosis, often revealing abnormalities earlier and in greater detail than chest radiography. However, traditional CT descriptors have provided limited diagnostic specificity. Consolidation, nodules, cavitation, and pleural effusion are common but nonspecific findings that overlap extensively with other infectious and noninfectious processes. As a result, radiologic suspicion for nocardiosis has historically depended more on clinical context than on imaging pattern recognition. The true clinical utility of the Wang et al’s study[3] lies in its translation of imaging observations into a triage mechanism. The identification of consolidation accompanied by nodules and cavitation as a dominant pattern is a key diagnostic clue. This triad, particularly when lobar or multilobar, is highly evocative in the appropriate setting. The study adds further precision by correlating imaging with microbiological species, noting that while Nocardia wallacei may present as bronchopneumonia, other species are strongly linked to this consolidated, destructive pattern[3].

Two additional findings from the study are critical risk modifiers for the radiologist and clinician. First, immunosuppressed patients, including transplant recipients, those on corticosteroids, or individuals with hematologic malignancies, exhibit “more diverse and complex imaging features”[3]. In these patients, a lower threshold for suspicion is warranted. Second, the identification of bronchiectasis as the most common comorbidity is profound[3]. Whether it acts as a predisposing structural abnormality facilitating colonization or results from chronic infection, its presence alongside new respiratory symptoms and a compatible CT pattern significantly raises the probability of nocardiosis[2].

MNGS: FROM CONFIRMATORY TOOL TO FIRST-LINE AGENT

Traditional diagnostic approaches for nocardiosis, including microscopy and culture, have severe limitations. Microscopy, while rapid, lacks specificity. Culture, though definitive, is hampered by slow growth (typically 2-14 days, but sometimes weeks) and can be inhibited by prior antibiotic therapy or overgrown by commensals[1,4]. This delay directly compromises patient care. Wang et al[3] correctly identify mNGS as a key diagnostic tool. It is imperative to recognize that its role may be evolving from a rescue diagnostic modality toward earlier use in carefully selected high-risk scenarios. mNGS offers culture-independent, unbiased detection of microbial nucleic acids in clinical samples, providing species-level identification and often antimicrobial resistance markers within 24-48 hours[5,6].

In the study by Wang et al[3], 60% of pulmonary nocardiosis cases were diagnosed using mNGS of sputum or bronchoalveolar lavage fluid, whereas concurrent culture identified Nocardia in only 3.3% of these cases. This dramatic discrepancy underscores the limited sensitivity of traditional culture methods and explains, at least in part, the rising incidence of diagnosed nocardiosis in recent years. Importantly, mNGS does more than improve detection rates; it enables reliable species-level identification. This capability has profound implications for radiology, as it allows retrospective and prospective correlation between imaging phenotypes and specific pathogens. Without mNGS, the species-level imaging distinctions reported in this cohort would likely have remained obscured, reinforcing the erroneous perception of radiologic uniformity in nocardial infections. In a patient with high-risk clinical and radiologic features, waiting for culture confirmation is an increasingly untenable strategy. While cost is often cited as a barrier, a holistic value assessment must account for the expenses of prolonged hospitalization, extended courses of broad-spectrum empiric antibiotics, and the significant morbidity of delayed effective therapy.

Despite its diagnostic promise, mNGS is not without limitations. False-positive results may arise from environmental contamination or detection of nonviable organisms. Furthermore, distinguishing between colonization and actual infection remains difficult, particularly in patients with persistent structural lung illness such bronchiectasis. Variability in bioinformatic pipelines, lack of standardized thresholds, and cost considerations may also restrict universal implementation[6]. Accordingly, mNGS should be interpreted within the broader clinical and radiologic context rather than as a standalone determinant of infection.

AN INTEGRATED DIAGNOSTIC ALGORITHM

Building upon the evidence presented by Wang et al[3], we propose a streamlined, imaging-initiated diagnostic algorithm for pulmonary nocardiosis.

Step 1 - imaging triage

A high-resolution chest CT is used to activate this route. Consolidation and nodules/cavities, particularly in a patient with documented immunosuppression or underlying bronchiectasis, should prompt a “high clinical suspicion” for nocardiosis. This is the most important decision point.

Step 2 - strategic sample acquisition

Upon high radiologic suspicion, clinicians should promptly obtain a high-quality lower respiratory tract sample. Bronchoalveolar lavage is optimal, providing ample material for all necessary tests. For focal lesions, CT-guided biopsy may be appropriate.

Step 3 - parallel testing

This is the core of the new paradigm. The sample must be sent to the laboratory with explicit instructions for parallel processing: Routine culture and stains alongside mNGS. The reflexive wait for culture results before considering advanced testing may warrant re-evaluation in settings where rapid molecular diagnostics are available.

Step 4 - actionable reporting and treatment

The rapid mNGS result provides a definitive or highly probable microbiological diagnosis. This allows clinicians to initiate or narrow antimicrobial therapy days or weeks before culture confirmation, guided by species identification and resistance markers. Conventional culture remains essential for obtaining a live isolate for definitive susceptibility testing.

This algorithm represents a proposed, expert opinion-based framework intended to guide clinical consideration and should not be interpreted as a validated diagnostic guideline.

Implications and future directions

This integrated approach redefines roles across specialties. For radiologists, their interpretation becomes the vital trigger for a precision diagnostic cascade, elevating their role in the management team. For pulmonologists and intensivists, it provides a clear action plan when faced with a concerning CT, reducing diagnostic paralysis. For microbiologists and infectious disease specialists, it validates the frontline use of molecular tools and fosters closer collaboration with radiology[5,7]. Future research must focus on prospectively validating this algorithm in multi-center studies. Rigorous cost-effectiveness analyses comparing early mNGS to standard pathways are needed to inform institutional protocols. Technological advancements, such as faster, more affordable mNGS platforms and improved bioinformatic pipelines to differentiate colonization from infection, will further solidify its role. Exploring the utility of mNGS on less invasive samples (e.g., sputum) in patients with high-volume disease could broaden applicability[7]. Prospective multicenter studies evaluating diagnostic yield, patient outcomes, and cost-effectiveness will be essential to determine whether imaging-guided early mNGS testing translates into measurable clinical benefit.

CONCLUSION

In the modern diagnostic era, coupling this “morphology-first” triage with the rapid, precise capabilities of mNGS might offer meaningful clinical value when applied in appropriately selected high-risk patients. We must integrate these tools into a cohesive and efficient diagnostic algorithm, ensuring that the insights from this pivotal study translate directly into faster diagnoses, more targeted therapy, and improved outcomes for patients confronting this formidable infection.

ACKNOWLEDGEMENTS

Thanks to Squad Medicine and Research for their support and guidance.